Why empowering both parties with the tools and data they need to make clinical decisions should be a top priority in the AI renaissance—to bolster patient care and improve health outcomes.
Kyle Kiser
Advertisement
Articles by Kyle Kiser
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Tylenol Maker Sued While Kennedy Says No ‘Sufficient’ Evidence for Autism Link
2
Novo Nordisk’s Unsolicited Proposal to Acquire Metsera
3
Pharmaceutical Executive Daily: Thermo Fisher's $8.8 Billion Acquisition of Clario Holdings
4
Dropping US Vaccine Rates Cause Delay in CSL’s Plans to Spin Off Vaccine Division
5
